Crinetics Pharmaceuticals, Inc. — Director's Dealing 2021

Jul 28, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Crinetics Pharmaceuticals, Inc. (CRNX)
CIK: 0001658247
Period of Report: 2021-07-26

Reporting Person: Fust Matthew K (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-07-26	Common Stock	M	5000	$1.91	Acquired	17536	Direct
2021-07-26	Common Stock	S	5000	$19.59	Disposed	12536	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-07-26	Non-qualified stock option (Right to Buy)	$1.91	M	5000	Disposed	2028-03-16	Common stock (5000)	Direct

Footnotes

F1: The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person at least 30 days prior to the trading date.

F2: Stock option granted March 17, 2018 with one-third vesting on the first anniversary of the grant date and the remainder vesting in a series of twenty-four (24) successive equal monthly installments thereafter.

F3: The common stock was sold by the reporting person in open market transactions on the transaction date, with a volume weighted average sales price of $19.59. The range of sales prices on the transaction date was $19.53 to $20.00 per share. Detailed information on the exact number of shares sold at each sale price can be obtained from the issuer upon request.